Alebund Pharmaceuticals (09637.HK) Launches IPO: Offer Price at HK$22.60 per Share, Listing Expected June 29

Newtimespace.com reports: Alebund Pharmaceuticals (Jiangsu) Co., Ltd. (Stock Code: 09637) announced details of its global offering, proposing to issue 56,755,400 H-shares. The Hong Kong public offering comprises 5,675,600 H-shares, representing approximately 10.0% of the total offering shares initially available; the international offering comprises 51,079,800 H-shares, representing approximately 90.0%. The offer price is HK$22.60 per share, with a board lot of 100 H-shares. The H-shares are expected to commence trading on the Stock Exchange on June 29, 2026.

The Hong Kong public offering opens at 9:00 a.m. on June 18, 2026, and closes at 12:00 noon on June 24, 2026. Applications may be submitted via the White Form eIPO service or the HKSCC EIPO channel. The expected price determination date is on or before June 24, 2026. The amount payable for 100 H-shares is HK$2,282.79, including brokerage commission, SFC transaction levy, Stock Exchange trading fee, and AFRC transaction levy.

Jefferies, BofA Securities, and HTSC (Huatai International) act as joint sponsors, sponsor-overall coordinators, overall coordinators, joint global coordinators, joint bookrunners, and joint lead managers; CLSA Limited and BOCI act as overall coordinators, joint global coordinators, joint bookrunners, and joint lead managers.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.